Drug intelligence / Profile preview

adjuvanted avian influenza ferritin nanoparticle vaccine

Development stage: Preclinical
Lead developer: Dyadic International
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular, Intranasal, Intratracheal, Ophthalmic, In Ovo

Overview

The adjuvanted avian influenza ferritin nanoparticle vaccine is a vaccine candidate developed through a collaboration between Dyadic International and ViroVax. It is designed to target avian influenza (H5N1, commonly known as 'Bird Flu') using Dyadic's C1 platform. Preclinical studies conducted in rabbits have demonstrated its ability to elicit robust neutralizing antibody responses. The vaccine aims to provide a scalable and low-cost solution for both human and animal use.

Beyond the preview

Go deeper on adjuvanted avian influenza ferritin nanoparticle vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adjuvanted avian influenza ferritin nanoparticle vaccine.

Explore the full profile